Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13901974 | 1.00 | CYP3A4 (0.31) | CYP3A4SLC7A5NOS2CYP1A2 | |
| SCHEMBL18819939 | 1.00 | CYP3A4 (0.31) | CYP3A4SLC7A5NOS2CYP1A2 | |
| SCHEMBL1117817 | 0.88 | SLC15A1 (0.33) | — | |
| SCHEMBL15292000 | 0.87 | SLC15A1 (0.40) | CYP3A4SLC7A5CYP1A2 | |
| SCHEMBL16256661 | 0.85 | CYP3A4 (0.32) | CYP3A4SLC7A5NOS2CYP1A2 | |
| SCHEMBL15214443 | 0.85 | CYP3A4 (0.32) | CYP3A4SLC7A5CYP1A2 | |
| SCHEMBL19173325 | 0.85 | CYP3A4 (0.32) | CYP3A4SLC7A5CYP1A2 | |
| SCHEMBL14693191 | 0.85 | CPB2 (0.31) | — | |
| SCHEMBL18408792 | 0.85 | LTA4H (0.36) | — | |
| Histidine SCHEMBL23756735 | 0.84 | SLC7A5 (0.42) | CYP3A4SLC7A5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039850-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | SABAG-RFA LTD. (IL) | 2016-02-11 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039850-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | NFATC1, KPNA2, KPNA6 | CYP3A4 4877/4885SLC7A5 1787/4885NOS2 3873/4885 |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | CYP3A4 4440/4885SLC7A5 2256/4885NOS2 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.